September 25, 2021

Merck and Vesselon Preclinical Study Reports Dramatic Tumor Pharmacokinetics Findings

Complete regression of both primary and distant tumors in 44% of enrolled subjects achieved with intravenous administration.

August 7, 2019

Vesselon Acquires FDA Approved Lipid Microsphere Imagent

“By changing the rate of progression or stopping cancer in its tracks, Vesselon can change the cancer landscape.”

August 24, 2021

Sonoporation-Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression

Sonoporation, the temporal cell membrane openings that can arise after ultrasound exposure, has been explored across many preclinical applications but has lacked translational momentum.